Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

GILD, SILA, PROT - Stock Alerts! from - Gilead Sciences, Gold American Mining, Proteonomix

|Includes: Gilead Sciences, Inc. (GILD)







  Gold American Mining Corp. (OTC:SILA)

SILA, a development stage company, focuses on the acquisition, exploration, and development of mineral resource properties in North America. SILA primarily explores for silver and gold deposits. SILA's properties include Keeno Strike project, which is located in the Clark county, Nevada; and Guadalupe project that is located in Zacatecas State, Mexico. SILA was formerly known as Silver America, Inc. and changed its name to Gold American Mining Corp. on June 23, 2010. SILA was founded in 2007 and is based in Reno, Nevada.

SILA is pleased to announce that it has received the final ground geophysics report on its Guadalupe property and confirms that the recently concluded geophysics program has identified multiple potentially significant geophysical anomalies.

The geophysical survey was designed to test down to depths of 500 metres. The key results from the geophysics program are:

  • Magnetic susceptibility survey was successful in identifying the trace near the surface extensions of the known veins. The presence of additional parallel anomalies suggests the potential for additional veins that do not outcrop.
  • Induced Polarization anomalies indicate the potential for down dip extensions to the main veins within the property.
  • A potentially significant chargeability anomaly (Induced Polarization) occurs in the southern portion of the property in between the Santa Rosa and San Antonio Mines at depth starting at 400 m, which is below the known depth of these historically important mines.

"The final results and interpretation of the geophysics results on our Guadalupe property have given us very attractive drilling targets. We are in the process of acquiring firm bids from several qualified drilling contractors and initiating the permitting process for the next phase of exploration of this exciting project," commented Johannes Petersen, President of SILA. "Gold American is well on track to initiating drilling operations on Guadalupe during the fourth quarter of 2010," added Mr. Petersen.


The Guadalupe property contains two historically significant mines and is located in one of Mexico's oldest mining districts, roughly 5 miles north of the Fresnillo (Proaño) Mine, the world's richest underground silver mine, operated by Fresnillo plc. Roughly 6.8 miles to the southwest of SILA's Guadalupe Property is the Juanicipio Joint Venture (JV) between MAG Silver Corp. (NYSEMKT:MAG) and Fresnillo plc, which is known as one of the world's highest grade undeveloped silver resources.

The Property contains greater than 20 known workings as well as two historic mines -- Santa Rita and San Antonio. Historic records containing references to the Santa Rita and San Antonio mines suggest that both mines were important and reached their height of production between 1910 and 1920 but were last in production in the 1980s. The property is completely surrounded by land controlled by Peñoles (either through Fresnillo or other subsidiaries and partners).

To learn more about SILA visit:


  Proteonomix, Inc. (OTCPK:PROT)

PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. PROT offers product for the treatment of anti-aging and damaged skin. PROT develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology. PROT also involves in the operation of retail Web site, to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue. In addition, PROT develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration. Further, PROT is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.

PROT has announced that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

"PROT has made great strides recently," stated Mr. Cohen, "and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships."

To learn more about PROT visit:


  Gilead Sciences, Inc. (Nasdaq:GILD)

GILD today announced that its corporate presentation will be webcast from the UBS Global Life Sciences Conference in New York.

John C. Martin, PhD, Gilead’s Chairman and Chief Executive Officer, will provide an overview of the company on Monday, September 20 at 1:00 p.m. Eastern Daylight Time.

To access the live webcast via the internet log on to Please connect to GILD’s website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

GILD, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. GILD's products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. GILD's products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. GILD's products under the Phase III clinical trials consist of Ambrisentan, an oral endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; and combination of tenofovir disoproxil fumarate, emtricitabine, and TMC278 for the treatment of HIV/AIDS in treatment-naive patients. GILD's Phase II clinical trials products comprise Aztreonam, Cicletanine, Cobicistat, combination of elvitegravir, cobicistat, and Truvada, GS 9190, GS 9310/11, and GS 9450, as well as Ranolazine that is preparing for Phase II clinical trials. GILD's Phase I clinical trials products include GS 6201, GS 9256, GS 9411, and GS 9667. GILD was founded in 1987 and is headquartered in Foster City, California.

To learn more about GILD visit:



Signup for FREE Daily Stock Alerts From 


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received eight thousand dollars in cash from a third party (Winning Media) for (1) day of advertising for Gold American Mining Corp (OTC:SILA) Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT)